In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.
Publication
, Journal Article
Pisetsky, DS
Published in: Ann Intern Med
August 2023
Smith RM, Jones RB, Specks U, et al; RITAZAREM co-investigators. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023;82:937-944. 36958796.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
August 2023
Volume
176
Issue
8
Start / End Page
JC95
Location
United States
Related Subject Headings
- Rituximab
- Remission Induction
- Recurrence
- Randomized Controlled Trials as Topic
- Immunosuppressive Agents
- Humans
- General & Internal Medicine
- Cyclophosphamide
- Chronic Disease
- Azathioprine
Citation
APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2023). In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo. Ann Intern Med, 176(8), JC95. https://doi.org/10.7326/J23-0057
Pisetsky, David S. “In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.” Ann Intern Med 176, no. 8 (August 2023): JC95. https://doi.org/10.7326/J23-0057.
Pisetsky DS. In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo. Ann Intern Med. 2023 Aug;176(8):JC95.
Pisetsky, David S. “In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.” Ann Intern Med, vol. 176, no. 8, Aug. 2023, p. JC95. Pubmed, doi:10.7326/J23-0057.
Pisetsky DS. In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo. Ann Intern Med. 2023 Aug;176(8):JC95.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
August 2023
Volume
176
Issue
8
Start / End Page
JC95
Location
United States
Related Subject Headings
- Rituximab
- Remission Induction
- Recurrence
- Randomized Controlled Trials as Topic
- Immunosuppressive Agents
- Humans
- General & Internal Medicine
- Cyclophosphamide
- Chronic Disease
- Azathioprine